



## **Industry Press Release**

**Date: 23 May 2023**

**Company: AstraZeneca**

**Media contact, Contact email and phone number:**

Flavia Garcia, [flavia.garcia@astrazeneca.com](mailto:flavia.garcia@astrazeneca.com) Jillian Gonzales,  
[jillian.gonzales@astrazeneca.com](mailto:jillian.gonzales@astrazeneca.com)

**Title of Press Release:** New AstraZeneca data presented at ATS 2023 strengthen the body of evidence supporting early intervention with *Breztri* in COPD

**Link to Press Release:** <https://www.astrazeneca.com/media-centre/medical-releases/new-astrazeneca-data-presented-at-ats-2023-strengthen-the-body-of-evidence-supporting-early-intervention-with-breztri-in-copd.html>

**Lead Paragraph:**

Results from the EROS real-world retrospective study showed that initiating fixed-dose triple-combination therapy *Breztri* *Aerosphere* (budesonide/glycopyrronium/formoterol fumarate) within 30 days of a qualifying moderate or severe exacerbation in patients with COPD (chronic obstructive pulmonary disease) is associated with a decreased risk of future exacerbations by 24% vs. delaying treatment by one to six months, and by 34% vs. delaying treatment six months to one year.<sup>1</sup>

1. Pollack, M, Tkacz, J, Schinkel, J. et al. Exacerbations and real-world outcomes (EROS) among patients with COPD receiving single inhaler triple therapy of budesonide/glycopyrrolate/formoterol fumarate [Poster Discussion]. Presented at the American Thoracic Society International Conference 2023 (19-24 May)